Marker Therapeutics, Inc.

MRKRSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1094038

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	—	—	—	$500.0K	—
Research and Development Expense	$10.4M	$12.0M	$27.8M	$18.9M	$12.8M
Operating Expenses	$17.9M	$23.3M	$40.7M	$29.4M	$22.7M
Operating Income (Loss)	-$14.6M	-$19.8M	-$39.5M	-$28.9M	-$22.5M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$14.0M	-$19.8M	—	—	—
Income Tax Expense (Benefit)	$3.7K	$3.7K	—	—	—
Net Income (Loss) Attributable to Parent	-$8.2M	-$29.9M	-$41.9M	-$28.7M	-$21.4M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$17.1M	$34.4M	$68.1M	$45.6M	$46.4M
Assets, Current	$17.1M	$16.6M	$46.0M	$24.4M	$45.5M
Cash and Cash Equivalents, at Carrying Value	$15.1M	$11.8M	$42.4M	$21.4M	$43.9M
Liabilities	$3.1M	$14.8M	$24.1M	$18.3M	$2.3M
Liabilities, Current	$3.1M	$7.8M	$12.9M	$6.4M	$2.0M
Accounts Payable, Current	$961.0K	$1.1M	$5.1M	$2.9M	$993.0K
Stockholders' Equity Attributable to Parent	$19.6M	$44.0M	$27.3M	$44.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$16.4M	-$27.0M	-$27.3M	-$20.0M	-$18.3M
Net Cash Provided by (Used in) Investing Activities	$18.7M	-$4.9M	-$3.1M	-$9.3M	-$375.0K
Net Cash Provided by (Used in) Financing Activities	$1.1M	$202.1K	$52.6M	$6.7M	$816.5K
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)